Idera Pharmaceuticals, Inc. (IDRA) Financial Analysis & Valuation | Quarter Chart
Idera Pharmaceuticals, Inc. (IDRA)
IDRAPrice: $0.42
Fair Value: 🔒
🔒score
Idera Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for rare disease indications in the United States. It offers Tilsotolimod (IMO-2125), a synthetic phosphorothioate oligonucleotide that acts as a direct agonist of TLR9 to ... more
Idera Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and... more
Description
Shares
| Market Cap | $0 | Exchange | NASDAQ |
| Sector | Healthcare | Industry | Biotechnology |
| Country | US | CEO | Vincent J. Milano |
| IPO Date | 1996-01-25 | CAGR | — |
| Employees | 13 | Website | www.iderapharma.com |
| Div. Yield | — | Payout Ratio | — |
| Buy Back Yield | — | Total Yield | — |
IDRA chart loading...
Fundamentals
Technicals
| Enterprise Value | $-1.62M | P/E Ratio | — |
| Forward P/E | — | PEG Ratio | — |
| P/S Ratio | — | P/B Ratio | 0.12 |
| P/CF Ratio | -0.06 | P/FCF Ratio | — |
| EPS | — | EPS Growth 1Y | — |
| EPS Growth 3Y | — | EPS Growth 5Y | — |
| Revenue Growth 1Y | — | Gross Margin | — |
| Operating Margin | — | Profit Margin | — |
| ROE | -1.13% | ROA | -0.23% |
| ROCE | -0.35% | Current Ratio | 0.83 |
| Quick Ratio | 0.83 | Cash Ratio | 0.56 |
| Debt/Equity | 0.05 | Interest Coverage | -136.36 |
| Altman Z Score | — | Piotroski Score | — |